{"protocolSection":{"identificationModule":{"nctId":"NCT05051579","orgStudyIdInfo":{"id":"18210"},"secondaryIdInfos":[{"id":"J2A-MC-GZGI","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"2021-002805-88","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities","officialTitle":"A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities"},"statusModule":{"statusVerifiedDate":"2023-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-09-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-08-25","type":"ACTUAL"},"completionDateStruct":{"date":"2022-11-22","type":"ACTUAL"},"studyFirstSubmitDate":"2021-09-17","studyFirstSubmitQcDate":"2021-09-17","studyFirstPostDateStruct":{"date":"2021-09-21","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-08-23","resultsFirstSubmitQcDate":"2023-08-23","resultsFirstPostDateStruct":{"date":"2023-09-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-23","lastUpdatePostDateStruct":{"date":"2023-09-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight."},"conditionsModule":{"conditions":["Obesity","Overweight and Obesity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":272,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"12 milligram (mg) LY3502970","type":"EXPERIMENTAL","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.","interventionNames":["Drug: LY3502970"]},{"label":"24 mg LY3502970","type":"EXPERIMENTAL","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.","interventionNames":["Drug: LY3502970"]},{"label":"36 mg-1 LY3502970","type":"EXPERIMENTAL","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.","interventionNames":["Drug: LY3502970"]},{"label":"36 mg-2 LY3502970","type":"EXPERIMENTAL","description":"Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.","interventionNames":["Drug: LY3502970"]},{"label":"45 mg-1 LY3502970","type":"EXPERIMENTAL","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.","interventionNames":["Drug: LY3502970"]},{"label":"45 mg-2 LY3502970","type":"EXPERIMENTAL","description":"Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.","interventionNames":["Drug: LY3502970"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received placebo administered orally once daily until 36 weeks.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"LY3502970","description":"Administered orally","armGroupLabels":["12 milligram (mg) LY3502970","24 mg LY3502970","36 mg-1 LY3502970","36 mg-2 LY3502970","45 mg-1 LY3502970","45 mg-2 LY3502970"]},{"type":"DRUG","name":"Placebo","description":"Administered orally","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percent Change From Baseline in Body Weight in LY3502970 and Placebo","description":"Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","timeFrame":"Baseline, Week 26"}],"secondaryOutcomes":[{"measure":"Percent Change From Baseline in Body Weight in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","timeFrame":"Baseline, Week 36"},{"measure":"Change From Baseline in Body Weight in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","timeFrame":"Baseline, Week 26"},{"measure":"Change From Baseline in Body Weight in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","timeFrame":"Baseline, Week 36"},{"measure":"Change From Baseline in Waist Circumference in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","timeFrame":"Baseline, Week 26"},{"measure":"Change From Baseline in Waist Circumference in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","timeFrame":"Baseline, Week 36"},{"measure":"Change From Baseline in BMI in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","timeFrame":"Baseline, Week 26"},{"measure":"Change From Baseline in BMI in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","timeFrame":"Baseline, Week 36"},{"measure":"Percentage of Participants With >=5% Body Weight Loss","description":"Percentage of participants with \\>=5% body weight loss was reported.","timeFrame":"Week 26"},{"measure":"Percentage of Participants With >=10% Body Weight Loss","description":"Percentage of participants with \\>=10% body weight loss was reported.","timeFrame":"Week 26"},{"measure":"Percentage of Participants With >=5% Body Weight Loss","description":"Percentage of participants with \\>=5% body weight loss was reported.","timeFrame":"Week 36"},{"measure":"Percentage of Participants With >=10% Body Weight Loss","description":"Percentage of participants with \\>=10% body weight loss was reported.","timeFrame":"Week 36"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)\n* Have a BMI ≥27 kg/m² and \\<30 kg/m² with at least 1 of the following weight-related comorbidities eg; \\[Have hypertension, or dyslipidemia, cardiovascular disease\\]\n* Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)\n\nExclusion Criteria:\n\n* Have any prior diagnosis of diabetes\n* Have a prior or planned surgical treatment for obesity\n* Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity\n* Have renal impairment measured as estimated glomerular filtration rate (eGFR) \\<30 milliliter (mL)/minute (min)/1.73 m²\n* Have a history of acute chronic pancreatitis\n* Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.\n\nWithin 3 months prior to screening:\n\n* Have poorly controlled hypertension\n* Have history of acute myocardial infarction\n* Have history of cerebrovascular accident (stroke)\n* Had hospitalization due to congestive heart failure (CHF)\n* Have cancer\n* Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening\n* Have hepatitis B and/or positive hepatitis B surface antigen","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-5615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Anaheim Clinical Trials, LLC","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"John Muir Physician Network Research Center","city":"Concord","state":"California","zip":"94520","country":"United States","geoPoint":{"lat":37.97798,"lon":-122.03107}},{"facility":"NorCal Medical Research, Inc","city":"Greenbrae","state":"California","zip":"94904","country":"United States","geoPoint":{"lat":37.94854,"lon":-122.5247}},{"facility":"Valley Clinical Trials, Inc.","city":"Northridge","state":"California","zip":"91325","country":"United States","geoPoint":{"lat":34.22834,"lon":-118.53675}},{"facility":"Norcal Endocrinology & Internal Medicine","city":"San Ramon","state":"California","zip":"94583","country":"United States","geoPoint":{"lat":37.77993,"lon":-121.97802}},{"facility":"Elite Clinical Trials","city":"Blackfoot","state":"Idaho","zip":"83221","country":"United States","geoPoint":{"lat":43.19047,"lon":-112.34498}},{"facility":"Rocky Mountain Clinical Research","city":"Idaho Falls","state":"Idaho","zip":"83404","country":"United States","geoPoint":{"lat":43.46658,"lon":-112.03414}},{"facility":"StudyMetrix Research","city":"City of Saint Peters","state":"Missouri","zip":"63303","country":"United States","geoPoint":{"lat":38.80033,"lon":-90.62651}},{"facility":"Premier Research","city":"Trenton","state":"New Jersey","zip":"08611","country":"United States","geoPoint":{"lat":40.21705,"lon":-74.74294}},{"facility":"Lillestol Research","city":"Fargo","state":"North Dakota","zip":"58104","country":"United States","geoPoint":{"lat":46.87719,"lon":-96.7898}},{"facility":"Intend Research, LLC","city":"Norman","state":"Oklahoma","zip":"73069","country":"United States","geoPoint":{"lat":35.22257,"lon":-97.43948}},{"facility":"Capital Area Research, LLC","city":"Camp Hill","state":"Pennsylvania","zip":"17011","country":"United States","geoPoint":{"lat":40.23981,"lon":-76.91997}},{"facility":"Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair","city":"Pittsburgh","state":"Pennsylvania","zip":"15243","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Dallas Diabetes Research Center","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Diabetes and Thyroid Center of Fort Worth","city":"Fort Worth","state":"Texas","zip":"76132","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Texas Diabetes & Endocrinology, P.A.","city":"Round Rock","state":"Texas","zip":"78681","country":"United States","geoPoint":{"lat":30.50826,"lon":-97.6789}},{"facility":"National Clinical Research, Inc","city":"Richmond","state":"Virginia","zip":"23294","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"St. Vincent Hospital d/b/a Prevea Health","city":"Green Bay","state":"Wisconsin","zip":"54303","country":"United States","geoPoint":{"lat":44.51916,"lon":-88.01983}},{"facility":"C-health Research","city":"Calgary","state":"Alberta","zip":"T2V 4J2","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Wharton Medical Clinic","city":"Hamilton","state":"Ontario","zip":"L8L 5G8","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Bluewater Clinical Research Group Inc.","city":"Sarnia","state":"Ontario","zip":"N7T 4X3","country":"Canada","geoPoint":{"lat":42.97866,"lon":-82.40407}},{"facility":"Centre Médical et Professionnel de l'Ouest de Portneuf","city":"Saint-Marc-des-Carrieres","state":"Quebec","zip":"G0A 4B0","country":"Canada","geoPoint":{"lat":46.68335,"lon":-72.0491}},{"facility":"Alpha Recherche Clinique","city":"Québec","zip":"G2J 0C4","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"ALPHA Recherche Clinique","city":"Québec","zip":"G3K 2P8","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Studium Egeszseghaz Kft","city":"Kalocsa","state":"Bács-Kiskun county","zip":"6300","country":"Hungary","geoPoint":{"lat":46.52981,"lon":18.97283}},{"facility":"Bugát Pál Kórház","city":"Gyöngyös","state":"Heves County","zip":"3200","country":"Hungary","geoPoint":{"lat":47.78257,"lon":19.928}},{"facility":"DRC Gyógyszervizsgáló Központ","city":"Balatonfüred","state":"Veszprém megye","zip":"8230","country":"Hungary","geoPoint":{"lat":46.96188,"lon":17.87187}},{"facility":"Kanizsai Dorottya Korhaz","city":"Nagykanizsa","state":"Zala County","zip":"8800","country":"Hungary","geoPoint":{"lat":46.45347,"lon":16.99104}},{"facility":"Szent Margit Rendelőintézet Nonprofit Kft","city":"Budapest","zip":"1032","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Clinexpert Kft.","city":"Budapest","zip":"1033","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"TRANTOR'99 Bt. Anyagcsere Centrum","city":"Budapest","zip":"1213","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Strazsahegy Medicina Bt.","city":"Budapest","zip":"H1171","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Debreceni Egyetem Klinikai Kozpont","city":"Debrecen","zip":"4032","country":"Hungary","geoPoint":{"lat":47.53167,"lon":21.62444}},{"facility":"Puerto Rico Medical Research","city":"Ponce","zip":"00717","country":"Puerto Rico","geoPoint":{"lat":18.01031,"lon":-66.62398}},{"facility":"Research and Cardiovascular Corp.","city":"Ponce","zip":"00717","country":"Puerto Rico","geoPoint":{"lat":18.01031,"lon":-66.62398}}]},"referencesModule":{"references":[{"pmid":"40481478","type":"DERIVED","citation":"Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J, Banerjee H, Pirro V, Kazda C, Mather K. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025 Jun 6;24(1):240. doi: 10.1186/s12933-025-02781-x."},{"pmid":"37351564","type":"DERIVED","citation":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M; GZGI Investigators. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023 Sep 7;389(10):877-888. doi: 10.1056/NEJMoa2302392. Epub 2023 Jun 23."}],"seeAlsoLinks":[{"label":"A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities","url":"https://trials.lillytrialguide.com/en-US/trial/1R7BP1Yw5t6roV3ZWFGzYQ"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"For maintenance doses of LY3502970: 12, 24, 36, and 45 milligram (mg), the initial dose will be 2 or 3 mg followed by additional escalation steps as appropriate. The dose-escalation varied by dose group where the target maintenance dose was achieved between Weeks 5 and 16.","groups":[{"id":"FG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"FG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"FG002","title":"36 mg -1 LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"FG003","title":"36 mg -2 LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"FG004","title":"45 mg -1 LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"FG005","title":"45 mg -2 LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"FG006","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"53"},{"groupId":"FG002","numSubjects":"29"},{"groupId":"FG003","numSubjects":"29"},{"groupId":"FG004","numSubjects":"31"},{"groupId":"FG005","numSubjects":"30"},{"groupId":"FG006","numSubjects":"50"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"46"},{"groupId":"FG002","numSubjects":"27"},{"groupId":"FG003","numSubjects":"24"},{"groupId":"FG004","numSubjects":"23"},{"groupId":"FG005","numSubjects":"28"},{"groupId":"FG006","numSubjects":"43"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}]},{"type":"Subject Unable to Visit Due to Working Out of Town","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Inadvertent Enrollment","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"}]},{"type":"Subject Could not Tolerate Investigational Product (IP) and was Taken Off","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Patient was Initially Long Term Follow-up But Contacted and came to Site After Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"BG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"BG002","title":"36 mg -1 LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"BG003","title":"36 mg -2 LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"BG004","title":"45 mg -1 LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"BG005","title":"45 mg -2 LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"BG006","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."},{"id":"BG007","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"29"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"30"},{"groupId":"BG006","value":"50"},{"groupId":"BG007","value":"272"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49.80","spread":"10.51"},{"groupId":"BG001","value":"57.00","spread":"9.09"},{"groupId":"BG002","value":"56.30","spread":"11.83"},{"groupId":"BG003","value":"55.40","spread":"10.93"},{"groupId":"BG004","value":"56.50","spread":"10.74"},{"groupId":"BG005","value":"50.90","spread":"12.58"},{"groupId":"BG006","value":"54.00","spread":"8.82"},{"groupId":"BG007","value":"54.20","spread":"10.67"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"16"},{"groupId":"BG006","value":"29"},{"groupId":"BG007","value":"161"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"21"},{"groupId":"BG007","value":"111"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"39"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"25"},{"groupId":"BG005","value":"22"},{"groupId":"BG006","value":"43"},{"groupId":"BG007","value":"223"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"10"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"19"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"25"},{"groupId":"BG004","value":"29"},{"groupId":"BG005","value":"30"},{"groupId":"BG006","value":"45"},{"groupId":"BG007","value":"247"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Canada","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"48"}]}]},{"title":"Hungary","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"31"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"22"},{"groupId":"BG006","value":"39"},{"groupId":"BG007","value":"193"}]}]}]},{"title":"Baseline Body Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Kilograms (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"107.49","spread":"25.34"},{"groupId":"BG001","value":"112.05","spread":"30.18"},{"groupId":"BG002","value":"107.78","spread":"22.45"},{"groupId":"BG003","value":"108.84","spread":"28.52"},{"groupId":"BG004","value":"105.23","spread":"20.40"},{"groupId":"BG005","value":"110.85","spread":"28.11"},{"groupId":"BG006","value":"107.57","spread":"25.24"},{"groupId":"BG007","value":"108.68","spread":"26.03"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Body Weight in LY3502970 and Placebo","description":"Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 26","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":"0.85"},{"groupId":"OG001","value":"-11.2","spread":"0.82"},{"groupId":"OG002","value":"-12.3","spread":"0.77"},{"groupId":"OG003","value":"-12.6","spread":"0.75"},{"groupId":"OG004","value":"-2.0","spread":"0.81"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-6.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.9","ciUpperLimit":"-4.2"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-9.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-11.5","ciUpperLimit":"-6.9"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-10.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.4","ciUpperLimit":"-8.0"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-10.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.7","ciUpperLimit":"-8.4"}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Body Weight in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent change","timeFrame":"Baseline, Week 36","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.4","spread":"1.05"},{"groupId":"OG001","value":"-12.5","spread":"1.01"},{"groupId":"OG002","value":"-13.5","spread":"0.95"},{"groupId":"OG003","value":"-14.7","spread":"0.94"},{"groupId":"OG004","value":"-2.3","spread":"1.00"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-7.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.9","ciUpperLimit":"-4.2"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-10.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.9","ciUpperLimit":"-7.3"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-11.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13.8","ciUpperLimit":"-8.4"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-12.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-15.0","ciUpperLimit":"-9.6"}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 26","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"0.90"},{"groupId":"OG001","value":"-12.3","spread":"0.86"},{"groupId":"OG002","value":"-12.9","spread":"0.82"},{"groupId":"OG003","value":"-13.3","spread":"0.79"},{"groupId":"OG004","value":"-2.1","spread":"0.86"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-6.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.3","ciUpperLimit":"-4.4"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-10.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.5","ciUpperLimit":"-7.8"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-10.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13.1","ciUpperLimit":"-8.5"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-11.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13.5","ciUpperLimit":"-8.9"}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body weight value.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline, Week 36","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.8","spread":"1.10"},{"groupId":"OG001","value":"-13.6","spread":"1.06"},{"groupId":"OG002","value":"-14.2","spread":"1.00"},{"groupId":"OG003","value":"-15.4","spread":"0.98"},{"groupId":"OG004","value":"-2.4","spread":"1.05"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-7.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.4","ciUpperLimit":"-4.3"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-11.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.2","ciUpperLimit":"-8.3"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-11.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.7","ciUpperLimit":"-9.0"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-13.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-15.8","ciUpperLimit":"-10.2"}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body waist circumference value.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"centimeter (cm)","timeFrame":"Baseline, Week 26","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","spread":"1.03"},{"groupId":"OG001","value":"-8.8","spread":"1.00"},{"groupId":"OG002","value":"-10.1","spread":"0.94"},{"groupId":"OG003","value":"-12.2","spread":"0.93"},{"groupId":"OG004","value":"-3.6","spread":"0.99"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"0.002","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-4.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.2","ciUpperLimit":"-1.6"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-5.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.0","ciUpperLimit":"-2.4"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-6.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.2","ciUpperLimit":"-3.8"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-8.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-11.3","ciUpperLimit":"-6.0"}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline body waist circumference value.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"cm","timeFrame":"Baseline, Week 36","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.6","spread":"1.18"},{"groupId":"OG001","value":"-11.2","spread":"1.15"},{"groupId":"OG002","value":"-10.6","spread":"1.06"},{"groupId":"OG003","value":"-13.6","spread":"1.07"},{"groupId":"OG004","value":"-4.0","spread":"1.12"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-5.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.8","ciUpperLimit":"-2.4"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-7.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.3","ciUpperLimit":"-4.0"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-6.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.7","ciUpperLimit":"-3.6"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-9.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.7","ciUpperLimit":"-6.6"}]},{"type":"SECONDARY","title":"Change From Baseline in BMI in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline BMI value.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilograms per meter square (kg/m^2)","timeFrame":"Baseline, Week 26","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"0.31"},{"groupId":"OG001","value":"-4.2","spread":"0.30"},{"groupId":"OG002","value":"-4.6","spread":"0.28"},{"groupId":"OG003","value":"-4.7","spread":"0.27"},{"groupId":"OG004","value":"-0.8","spread":"0.29"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-2.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.2","ciUpperLimit":"-1.6"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-3.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.3","ciUpperLimit":"-2.6"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-3.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.6","ciUpperLimit":"3.0"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-3.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.7","ciUpperLimit":"-3.1"}]},{"type":"SECONDARY","title":"Change From Baseline in BMI in LY3502970 and Placebo","description":"LS mean was determined by MMRM model with Baseline + Baseline BMI Group + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares) as variables. Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline BMI value.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg/m^2","timeFrame":"Baseline, Week 36","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"0.38"},{"groupId":"OG001","value":"-4.7","spread":"0.36"},{"groupId":"OG002","value":"-5.0","spread":"0.34"},{"groupId":"OG003","value":"-5.5","spread":"0.34"},{"groupId":"OG004","value":"-0.9","spread":"0.36"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-2.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.6","ciUpperLimit":"-1.5"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-3.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.8","ciUpperLimit":"-2.8"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-4.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.2","ciUpperLimit":"-3.2"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Mixed Models Analysis","paramType":"LS Mean difference (Final Values)","paramValue":"-4.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.6","ciUpperLimit":"-3.6"}]},{"type":"SECONDARY","title":"Percentage of Participants With >=5% Body Weight Loss","description":"Percentage of participants with \\>=5% body weight loss was reported.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for ≥5% body weight reduction.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 26","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.39"},{"groupId":"OG001","value":"88.84"},{"groupId":"OG002","value":"89.46"},{"groupId":"OG003","value":"87.26"},{"groupId":"OG004","value":"22.88"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"9.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.61","ciUpperLimit":"27.44"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"27.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.15","ciUpperLimit":"96.01"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"27.36","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.71","ciUpperLimit":"85.91"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"23.59","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.65","ciUpperLimit":"72.77"}]},{"type":"SECONDARY","title":"Percentage of Participants With >=10% Body Weight Loss","description":"Percentage of participants with \\>=10% body weight loss was reported.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for ≥10% body weight reduction.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 26","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.39"},{"groupId":"OG001","value":"56.61"},{"groupId":"OG002","value":"71.30"},{"groupId":"OG003","value":"69.86"},{"groupId":"OG004","value":"2.25"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"19.93","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.47","ciUpperLimit":"114.40"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"39.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"6.95","ciUpperLimit":"224.83"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"74.97","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"13.16","ciUpperLimit":"427.18"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"72.23","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"12.62","ciUpperLimit":"413.21"}]},{"type":"SECONDARY","title":"Percentage of Participants With >=5% Body Weight Loss","description":"Percentage of participants with \\>=5% body weight loss was reported.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for ≥5% body weight reduction.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 36","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.00"},{"groupId":"OG001","value":"89.47"},{"groupId":"OG002","value":"92.05"},{"groupId":"OG003","value":"90.44"},{"groupId":"OG004","value":"24.02"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"7.79","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.90","ciUpperLimit":"20.92"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"25.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.49","ciUpperLimit":"83.91"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"34.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.17","ciUpperLimit":"147.86"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"28.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.15","ciUpperLimit":"96.29"}]},{"type":"SECONDARY","title":"Percentage of Participants With >=10% Body Weight Loss","description":"Percentage of participants with \\>=10% body weight loss was reported.","populationDescription":"All randomized participants who received at least one dose of study drug and had baseline and at least one post-baseline value for ≥10% body weight reduction.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Week 36","groups":[{"id":"OG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks."},{"id":"OG002","title":"36 mg LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-1 and dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 in LY 36mg-2 administered orally once daily until 36 weeks."},{"id":"OG003","title":"45 mg LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-1 and dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 in LY 45mg-2 administered orally once daily until 36 weeks."},{"id":"OG004","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"48"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.50"},{"groupId":"OG001","value":"61.88"},{"groupId":"OG002","value":"74.75"},{"groupId":"OG003","value":"69.07"},{"groupId":"OG004","value":"8.85"}]}]}],"analyses":[{"groupIds":["OG000","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"8.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.59","ciUpperLimit":"26.45"},{"groupIds":["OG001","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"15.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.83","ciUpperLimit":"50.68"},{"groupIds":["OG002","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"27.24","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.39","ciUpperLimit":"88.38"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"20.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"6.59","ciUpperLimit":"66.17"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline through Week 38 (36 weeks with 2 weeks safety follow up)","description":"All randomized participants who received at least one dose of study drug regardless of adherence to study drug. Gender specific events occurring only in male or female participants have had the number of participants at risk adjusted accordingly.","eventGroups":[{"id":"EG000","title":"12 mg LY3502970","description":"Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"otherNumAffected":35,"otherNumAtRisk":50},{"id":"EG001","title":"24 mg LY3502970","description":"Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.","deathsNumAffected":0,"deathsNumAtRisk":53,"seriousNumAffected":2,"seriousNumAtRisk":53,"otherNumAffected":46,"otherNumAtRisk":53},{"id":"EG002","title":"36 Mg-1 LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.","deathsNumAffected":0,"deathsNumAtRisk":29,"seriousNumAffected":0,"seriousNumAtRisk":29,"otherNumAffected":23,"otherNumAtRisk":29},{"id":"EG003","title":"36 Mg-2 LY3502970","description":"Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.","deathsNumAffected":0,"deathsNumAtRisk":29,"seriousNumAffected":3,"seriousNumAtRisk":29,"otherNumAffected":25,"otherNumAtRisk":29},{"id":"EG004","title":"45 Mg-1 LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.","deathsNumAffected":0,"deathsNumAtRisk":31,"seriousNumAffected":2,"seriousNumAtRisk":31,"otherNumAffected":26,"otherNumAtRisk":31},{"id":"EG005","title":"45 Mg-2 LY3502970","description":"Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.","deathsNumAffected":0,"deathsNumAtRisk":30,"seriousNumAffected":0,"seriousNumAtRisk":30,"otherNumAffected":24,"otherNumAtRisk":30},{"id":"EG006","title":"Placebo","description":"Participants received placebo administered orally once daily until 36 weeks.","deathsNumAffected":0,"deathsNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"otherNumAffected":27,"otherNumAtRisk":50}],"seriousEvents":[{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Retinal vein thrombosis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Vitreoretinal traction syndrome","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Diverticulum intestinal","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Gastrointestinal polyp haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Hepatic cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]}],"otherEvents":[{"term":"Atrioventricular block first degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":53},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":50},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG005","numEvents":3,"numAffected":1,"numAtRisk":30},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":50}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":12,"numAtRisk":50},{"groupId":"EG001","numEvents":21,"numAffected":17,"numAtRisk":53},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":29},{"groupId":"EG003","numEvents":10,"numAffected":7,"numAtRisk":29},{"groupId":"EG004","numEvents":8,"numAffected":6,"numAtRisk":31},{"groupId":"EG005","numEvents":5,"numAffected":4,"numAtRisk":30},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":50}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":12,"numAtRisk":50},{"groupId":"EG001","numEvents":29,"numAffected":19,"numAtRisk":53},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":29},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":31},{"groupId":"EG005","numEvents":16,"numAffected":10,"numAtRisk":30},{"groupId":"EG006","numEvents":6,"numAffected":5,"numAtRisk":50}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":50},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":53},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG006","numEvents":4,"numAffected":3,"numAtRisk":50}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":9,"numAtRisk":50},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":53},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG005","numEvents":9,"numAffected":6,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":50}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":50},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":53},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":29},{"groupId":"EG004","numEvents":6,"numAffected":4,"numAtRisk":31},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":25,"numAtRisk":50},{"groupId":"EG001","numEvents":50,"numAffected":31,"numAtRisk":53},{"groupId":"EG002","numEvents":18,"numAffected":12,"numAtRisk":29},{"groupId":"EG003","numEvents":18,"numAffected":14,"numAtRisk":29},{"groupId":"EG004","numEvents":28,"numAffected":13,"numAtRisk":31},{"groupId":"EG005","numEvents":23,"numAffected":11,"numAtRisk":30},{"groupId":"EG006","numEvents":6,"numAffected":5,"numAtRisk":50}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":13,"numAtRisk":50},{"groupId":"EG001","numEvents":33,"numAffected":17,"numAtRisk":53},{"groupId":"EG002","numEvents":11,"numAffected":8,"numAtRisk":29},{"groupId":"EG003","numEvents":9,"numAffected":4,"numAtRisk":29},{"groupId":"EG004","numEvents":14,"numAffected":9,"numAtRisk":31},{"groupId":"EG005","numEvents":15,"numAffected":8,"numAtRisk":30},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":50}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":53},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":31},{"groupId":"EG005","numEvents":6,"numAffected":4,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":50},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":53},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":29},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":29},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":31},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":30},{"groupId":"EG006","numEvents":9,"numAffected":9,"numAtRisk":50}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":50},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":53},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":50},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":50}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":50},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":53},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":53},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":50}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":50},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":53},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":50},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":53},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG004","numEvents":6,"numAffected":4,"numAtRisk":31},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":30},{"groupId":"EG006","numEvents":7,"numAffected":5,"numAtRisk":50}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]},{"term":"Balanoposthitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":21}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":21}]},{"term":"Postmenopausal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Vulvovaginal pruritus","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":16},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG006","numEvents":2,"numAffected":1,"numAtRisk":50}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":50},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":53},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":50}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":50},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":53},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":29},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":30},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":50}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-09-27","uploadDate":"2023-08-08T01:56","filename":"Prot_000.pdf","size":5864017},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-10-03","uploadDate":"2023-08-08T01:57","filename":"SAP_001.pdf","size":1191356}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-08-29"},"conditionBrowseModule":{"meshes":[{"id":"D009765","term":"Obesity"},{"id":"D050177","term":"Overweight"}],"ancestors":[{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000729680","term":"orforglipron"},{"id":"D058110","term":"Counterfeit Drugs"}],"ancestors":[{"id":"D000078742","term":"Substandard Drugs"},{"id":"D004364","term":"Pharmaceutical Preparations"}]}},"hasResults":true}
